Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

Webster et al. • 2017

Br J Pharmacol. 2017;174(5):396-408.

28012176